Piper Sandler Reiterates Overweight on Omnicell, Lowers Price Target to $45
Piper Sandler analyst Jessica Tassan reiterates Omnicell (NASDAQ:OMCL) with a Overweight and lowers the price target from $55 to $45.
Read original at benzingaStocks · News reference
Omnicell Q2 Adj. EPS $0.94 Beats $0.47 Estimate, Sales $312.208M Beat $310.253M Estimate
Omnicell (NASDAQ:OMCL) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.47 by 100 percent. This is a 108.89 percent increase over earnings of $0.45 per share from the same
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 10:30 AM
- Checked
- Jul 30, 2026, 10:30 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wells Fargo Maintains Overweight on Omnicell, Lowers Price Target to $50
Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:OMCL) with a Overweight and lowers the price target from $55 to $50.
Read original at benzingaKeybanc Maintains Overweight on Omnicell, Lowers Price Target to $65
Read original at benzingaOmnicell shares are trading lower. The company reported Q2 financial results and issued Q3 guidance below analyst estimates.
Read original at benzinga